Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Endocrinology | Family Medicine | Internal Medicine | Nursing | Psychiatry | Journal

Back to Journal Articles

Team-Centered Multicondition Care Deemed Cost-Effective

Last Updated: May 10, 2012.

 

Collaborative care intervention lowers outpatient costs for comorbid psychiatric, medical disease

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For adults with depression and poorly controlled diabetes and/or coronary heart disease, a collaborative care intervention is cost-effective, according to a study published in the May issue of the Archives of General Psychiatry.

THURSDAY, May 10 (HealthDay News) -- For adults with depression and poorly controlled diabetes and/or coronary heart disease (CHD), a collaborative care intervention is cost-effective, according to a study published in the May issue of the Archives of General Psychiatry.

Wayne Katon, M.D., from the University of Washington in Seattle, and colleagues conducted a randomized controlled trial to assess the cost-effectiveness of a multicondition collaborative treatment program instituted at 14 primary care clinics of an integrated health care system. The study group included 214 adults with depressive disorder and poorly controlled diabetes or CHD. Depressive symptoms, systolic blood pressure (SBP), hemoglobin A1c (HbA1c), and low-density lipoprotein cholesterol (LDL-C) were evaluated at baseline and during 24 months of follow-up.

The researchers found that, over 24 months of follow-up, intervention patients had a mean of 114 additional depression-free days and an estimated 0.335 additional quality-adjusted life-years compared with controls receiving usual primary care. Compared with usual care patients, those in the intervention group also had lower mean outpatient health costs of $594 per patient.

"For adults with depression and poorly controlled diabetes, CHD, or both, a systematic intervention program aimed at improving depression scores and HbA1c, SBP, and LDL-C levels seemed to be a high-value program that for no or modest additional cost markedly improved quality-adjusted life-years," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Less Testing in ER for Children With Non-Private Insurance Next: Mid- and Late-Life Depression Tied to Dementia Risk

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.